Targeting mitochondria for treatment of chemoresistant ovarian cancer

Edith Emmings, Sally A Mullany, Zenas Chang, Charles N. Landen, Stig Linder, Martina Bazzaro

Research output: Contribution to journalReview article

Abstract

Ovarian cancer is the leading cause of death from gynecologic malignancy in the Western world. This is due, in part, to the fact that despite standard treatment of surgery and platinum/paclitaxel most patients recur with ultimately chemoresistant disease. Ovarian cancer is a unique form of solid tumor that develops, metastasizes and recurs in the same space, the abdominal cavity, which becomes a unique microenvironment characterized by ascites, hypoxia and low glucose levels. It is under these conditions that cancer cells adapt and switch to mitochondrial respiration, which becomes crucial to their survival, and therefore an ideal metabolic target for chemoresistant ovarian cancer. Importantly, independent of microenvironmental factors, mitochondria spatial redistribution has been associated to both tumor metastasis and chemoresistance in ovarian cancer while specific sets of genetic mutations have been shown to cause aberrant dependence on mitochondrial pathways in the most aggressive ovarian cancer subtypes. In this review we summarize on targeting mitochondria for treatment of chemoresistant ovarian cancer and current state of understanding of the role of mitochondria respiration in ovarian cancer. We feel this is an important and timely topic given that ovarian cancer remains the deadliest of the gynecological diseases, and that the mitochondrial pathway has recently emerged as critical in sustaining solid tumor progression.

Original languageEnglish (US)
Article number229
JournalInternational journal of molecular sciences
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Mitochondria
mitochondria
Ovarian Neoplasms
Tumors
cancer
Paclitaxel
Platinum
Surgery
Glucose
Therapeutics
tumors
Neoplasms
Cells
Switches
respiration
Respiration
Mitochondrial Diseases
Western World
Abdominal Cavity
causes

Keywords

  • Ascites
  • Chemoresistant ovarian cancer
  • Mitochondrial inhibitor
  • OXPHOS
  • SWI/SNF complex

Cite this

Targeting mitochondria for treatment of chemoresistant ovarian cancer. / Emmings, Edith; Mullany, Sally A; Chang, Zenas; Landen, Charles N.; Linder, Stig; Bazzaro, Martina.

In: International journal of molecular sciences, Vol. 20, No. 1, 229, 01.01.2019.

Research output: Contribution to journalReview article

@article{f9e1f988c5a9423d812a2165d0d0c6d1,
title = "Targeting mitochondria for treatment of chemoresistant ovarian cancer",
abstract = "Ovarian cancer is the leading cause of death from gynecologic malignancy in the Western world. This is due, in part, to the fact that despite standard treatment of surgery and platinum/paclitaxel most patients recur with ultimately chemoresistant disease. Ovarian cancer is a unique form of solid tumor that develops, metastasizes and recurs in the same space, the abdominal cavity, which becomes a unique microenvironment characterized by ascites, hypoxia and low glucose levels. It is under these conditions that cancer cells adapt and switch to mitochondrial respiration, which becomes crucial to their survival, and therefore an ideal metabolic target for chemoresistant ovarian cancer. Importantly, independent of microenvironmental factors, mitochondria spatial redistribution has been associated to both tumor metastasis and chemoresistance in ovarian cancer while specific sets of genetic mutations have been shown to cause aberrant dependence on mitochondrial pathways in the most aggressive ovarian cancer subtypes. In this review we summarize on targeting mitochondria for treatment of chemoresistant ovarian cancer and current state of understanding of the role of mitochondria respiration in ovarian cancer. We feel this is an important and timely topic given that ovarian cancer remains the deadliest of the gynecological diseases, and that the mitochondrial pathway has recently emerged as critical in sustaining solid tumor progression.",
keywords = "Ascites, Chemoresistant ovarian cancer, Mitochondrial inhibitor, OXPHOS, SWI/SNF complex",
author = "Edith Emmings and Mullany, {Sally A} and Zenas Chang and Landen, {Charles N.} and Stig Linder and Martina Bazzaro",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/ijms20010229",
language = "English (US)",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - Targeting mitochondria for treatment of chemoresistant ovarian cancer

AU - Emmings, Edith

AU - Mullany, Sally A

AU - Chang, Zenas

AU - Landen, Charles N.

AU - Linder, Stig

AU - Bazzaro, Martina

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ovarian cancer is the leading cause of death from gynecologic malignancy in the Western world. This is due, in part, to the fact that despite standard treatment of surgery and platinum/paclitaxel most patients recur with ultimately chemoresistant disease. Ovarian cancer is a unique form of solid tumor that develops, metastasizes and recurs in the same space, the abdominal cavity, which becomes a unique microenvironment characterized by ascites, hypoxia and low glucose levels. It is under these conditions that cancer cells adapt and switch to mitochondrial respiration, which becomes crucial to their survival, and therefore an ideal metabolic target for chemoresistant ovarian cancer. Importantly, independent of microenvironmental factors, mitochondria spatial redistribution has been associated to both tumor metastasis and chemoresistance in ovarian cancer while specific sets of genetic mutations have been shown to cause aberrant dependence on mitochondrial pathways in the most aggressive ovarian cancer subtypes. In this review we summarize on targeting mitochondria for treatment of chemoresistant ovarian cancer and current state of understanding of the role of mitochondria respiration in ovarian cancer. We feel this is an important and timely topic given that ovarian cancer remains the deadliest of the gynecological diseases, and that the mitochondrial pathway has recently emerged as critical in sustaining solid tumor progression.

AB - Ovarian cancer is the leading cause of death from gynecologic malignancy in the Western world. This is due, in part, to the fact that despite standard treatment of surgery and platinum/paclitaxel most patients recur with ultimately chemoresistant disease. Ovarian cancer is a unique form of solid tumor that develops, metastasizes and recurs in the same space, the abdominal cavity, which becomes a unique microenvironment characterized by ascites, hypoxia and low glucose levels. It is under these conditions that cancer cells adapt and switch to mitochondrial respiration, which becomes crucial to their survival, and therefore an ideal metabolic target for chemoresistant ovarian cancer. Importantly, independent of microenvironmental factors, mitochondria spatial redistribution has been associated to both tumor metastasis and chemoresistance in ovarian cancer while specific sets of genetic mutations have been shown to cause aberrant dependence on mitochondrial pathways in the most aggressive ovarian cancer subtypes. In this review we summarize on targeting mitochondria for treatment of chemoresistant ovarian cancer and current state of understanding of the role of mitochondria respiration in ovarian cancer. We feel this is an important and timely topic given that ovarian cancer remains the deadliest of the gynecological diseases, and that the mitochondrial pathway has recently emerged as critical in sustaining solid tumor progression.

KW - Ascites

KW - Chemoresistant ovarian cancer

KW - Mitochondrial inhibitor

KW - OXPHOS

KW - SWI/SNF complex

UR - http://www.scopus.com/inward/record.url?scp=85059795448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059795448&partnerID=8YFLogxK

U2 - 10.3390/ijms20010229

DO - 10.3390/ijms20010229

M3 - Review article

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 1

M1 - 229

ER -